-
Prolapse occurs along a spectrum from early and asymptomatic to advanced and symptomatic. The authors define anatomic cutoffs that are likely to result in symptomatic and clinically significant prolapse.
-
The authors enrolled women desiring postpartum use of a levonorgestrel-releasing intrauterine system in a randomized trial to determine whether use of the device would be higher when insertion occurred immediately postpartum rather than delaying placement to the standard postpartum visit.
-
In this issue: Rivaroxaban may be dabigatran's first competitor; a new way to measure non-adherence to medication therapy; FDA Actions.
-
The rate of sepsis with group b streptococcus (gbs) in neonates of colonized mothers is now less than 1%.
-
The authors randomized women with objectively validated heavy menstrual bleeding (mean menstrual blood loss [MBL] of 80 mL or more per cycle, confirmed using the alkaline hematin methodology during two pretreatment cycles) to treatment with oral tranexamic acid 3.9 g/d or placebo for up to 5 days per cycle for 6 menstrual cycles.
-
Nearly every reference source discussing the primary management of advanced ovarian cancer will highlight the role of surgical cytoreduction as an important first step in the care of this disease.
-
-
This trial was a randomized double-blind control trial of 89 women undergoing consecutive removal and replacement of a levonorgestrel-releasing intrauterine device (LNG-IUD). Of note, this study was part of a larger multicenter trial evaluating the bleeding profile and safety with repeat use of a LNG-IUD in women who had used their first device for close to 5 years.
-
Early Detection and Treatment of Ovarian Cancer Improves Outcome: Right?
-
